Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which lens gives sharper sight after cataracts? new trial aims to find out

NCT ID NCT07165197

Symptom relief Sponsor: OMIQ Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares two types of advanced lens implants (Clareon Vivity and PureSee) used in cataract surgery. Researchers want to see which lens provides better vision at far, intermediate, and near distances. The trial involves 80 adults aged 50 and older who need cataract surgery in both eyes. Participants will receive one lens type in each eye, and their vision will be tested over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
extended depth of focus intraocular lenses (Clareon Vivity and PureSee)
What this could lead to
If successful, this study could help doctors choose the best lens for cataract patients, potentially improving vision at multiple distances without glasses.
What could go wrong
This is a small, early-stage trial with only 80 participants, so results may not apply to everyone. Individual outcomes can vary, and not all patients may achieve perfect vision.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients of any sex and race aged 50 years or older * Patients undergoing bilateral age-related cataract surgery with a lens opacity grade 3 or higher in the LOCS III grading scale * Willing to receive implantation of an EDOF IOL * Willing to sign the informed consent and attend the study visits Exclusion Criteria: * Requirement of a spherical or toric power of the IOL to achieve emmetropia beyond the available range of either of the two lenses * The number of patients included with low astigmatism that require an equivalent to a T2 toric IOL will be capped to 10 patients/group * Irregular astigmatism * Contact lens wear in the previous 3 weeks before biometry * Moderate or severe ocular surface, corneal, macular or optic nerve disease that in opinion of the investigator precludes the desired functional results * History of previous refractive, cornea, retina or glaucoma surgery * Eyes with a clear lens demanding a refractive lens exchange * Amblyopia in any eye * Significant previous ocular trauma * Pregnancy * A systemic condition that, in the opinion of the investigator, precludes the reliable assessments required in the study (i.e., dementia) or participation in the study (i.e., severe mobility problems).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related cataract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cataract senile cataract

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataract

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • OMIQ Research

    RECRUITING

    Sant Cugat del Vallès, Barcelona, 08195, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.